VBI Vaccines, Inc. – (NASDAQ:VBIV) saw strong trading volume on Tuesday . 63,803 shares changed hands during trading, an increase of 4% from the previous session’s volume of 61,207 shares.The stock last traded at $3.93 and had previously closed at $3.85.

The firm’s 50 day moving average price is $4.00 and its 200-day moving average price is $4.01. The company’s market capitalization is $123.77 million.

An institutional investor recently bought a new position in VBI Vaccines, Inc. – stock. Cambridge Investment Research Advisors Inc. acquired a new position in VBI Vaccines, Inc. – (NASDAQ:VBIV) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,433,100 shares of the biopharmaceutical company’s stock, valued at approximately $3,497,000. Cambridge Investment Research Advisors Inc. owned 6.09% of VBI Vaccines, Inc. – as of its most recent SEC filing.

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.